Effectiveness of omalizumab (Xolair®) in the first patients treated in real-life practice in France
Authors:
- Mathieu MolimardMMMathieu Molimard
- Frédéric de BlayFBFrédéric de Blay
- Alain DidierADAlain Didier
- Vincent Le GrosVGVincent Le Gros
- 1 January 2008
- journal article
- Published by Elsevier in Respiratory Medicine
- Vol. 102 (1) , 71-76
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004
- Can Guideline-defined Asthma Control Be Achieved?American Journal of Respiratory and Critical Care Medicine, 2004
- Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLARAllergy, 2004
- Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthmaAllergy, 2004
- Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthmaClinical & Experimental Allergy, 2004
- Omalizumab is effective in the long-term control of severe allergic asthmaAnnals of Allergy, Asthma & Immunology, 2003
- Persistent asthma: disease control, resource utilisation and direct costsEuropean Respiratory Journal, 2002
- Omalizumab provides long-term control in patients with moderate-to-severe allergic asthmaEuropean Respiratory Journal, 2002
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmaticsEuropean Respiratory Journal, 2001